Clinical Efficacy and Safety of Trastuzumab Combined with FOLFOX4 Regimen in the Treatment of Advanced Gastric Cancer
Objective To investigate the clinical efficacy and safety of oxaliplatin,fluorouracil and leucovorin(FOLFOX4)regimen combined with trastuzumab in the treatment of patients with advanced gastric cancer.Methods 82 patients with advanced gastric cancer admitted to this hospital from October 2021 to October 2022 were selected as the research objects,and were divided into a control group and an observation group by random number table method.The control group(n=41)was treated with FOLFOX4 regimen alone,and the observation group(n=41)was treated with FOLFOX4 regimen and trastuzumab.The clinical remission rate,tumor markers,neovascularization markers,1-year survival rate,and adverse reactions were compared between the two groups.Results The clinical remission rate of the observation group was 85.37%,which was higher than 65.85%of the control group,and the difference was statistically significant(P＜0.05).Before treatment,the expressions of cytokeratin 19 fragment antigen 211(CYFRA211),carcinoembryonic antigen(CEA),carbohydrate antigen 153(CA153),pigment epithelium-derived factor(PEDF),endothelial cell s pecific molecule-1(ESM-1)and vascular endothelial growth factor(VEGF)were compared between the two groups.There was no significant difference between the two groups(P＞0.05);after treatment,in the observation group,CYFRA211 was(13.42±2.24)ng/mL,CEA was(25.72±3.35)ng/mL,CA153 was(37.59±4.06)U/mL,PEDF was(43.48±9.95)ug/L,ESM-1 was(0.74±0.19)ug/L,VEGF was(6 6.83±4.12)ng/L,which were lower than(15.19±3.06)ng/mL,(28.91±3.14)ng/mL,(39.95±6.11)U/mL,(47.85±9.68)ug/L,(0.99±0.15)ug/L,(70.75±5.05)ng/L in the control group,respectively.The differences between the two groups were statistically significant(P＜0.05).The 1-year survival rate of the observation group was 82.93%,which was higher than 63.41%of the control group,and the difference was statistically significant(P＜0.05).Comparison of adverse reactions between two groups,the differences was not statistically significant(P＞0.05).Conclusion FOLFOX4 chemotherapy combined with trastuzumab can down-regulate the expression of tumor markers,inhibit tumor angiogenesis and improve survival rate in patients with advanced gastric cancer.The disease remission effect is definite,and the safety is high,and no serious adverse reactions occur.
NETL
NSTL
万方数据
